Board of Directors of Ozon Pharmaceuticals recommended that dividends be paid for 9 months 2025 in the amount of ₽0.27 per ordinary share. The last day of the purchase of securities to receive dividends is January 9, 2026. Dividend yield may amount to 0.53%.

Sales of Ozon Pharmaceuticals for 9 months of 2025 amounted to 241.5 million packages of medicines, an increase of 8% compared to the previous year. In the public procurement segment, sales increased by 19% to 76.7 million packages. Retail sales increased by 4% to 164.8 million packages.

Board of Directors of Ozon Pharmaceuticals approved the sale of 12,927,030 quasi-treasury shares of the company, which make up 1.1% of the authorized capital. Management plans to gradually sell shares to the market during 2025 and 2026 with minimal impact on the quotation.

Ozon Pharmaceuticals' net profit under IFRS for 9 months of 2025 amounted to 3.5 billion rubles, an increase of 52.2% compared to 2.3 billion rubles in the previous year. Revenue increased by 27.4% to ₽21.4 billion from ₽16.8 billion a year earlier.